Identification of α-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes

Clinical Cancer Research

Volumn 12, Issue 19, 2006, Pages 5746-5754

  Chang, Gee Chen ^a,b,c   Liu, Ko Jiunn ^e   Hsieh, Chia Ling ^e   Hu, Tsai Shu ^e   Charoenfuprasert, Suparat ^f   Liu, Hsiung Kun ^e   Luh, Kwen Tay ^g   Hsu, Li Han ^h   Wu, Chew Wen ⁱ   Ting, Chou Chik ^e   Chen, Chih Yi ^a,d   Chen, Kun Chieh ^a   Yang, Tsung Ying ^a   Chou, Teh Ying ⁱ   Wang, Wen Hua ^j   Whang Peng, Jacqueline ^e   Shih, Neng Yao ^e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h Sun Yat Sen Cancer Center   (Taiwan)

ⁱ TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^j CARDINAL TIEN HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; AUTOANTIGEN; P48 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN PURIFICATION; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS EPITHELIUM; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; AUTOANTIGENS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PHOSPHOPYRUVATE HYDRATASE; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750285970     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0324     Document Type: Article

References (44)

1. Andrews BS, Arora NS, Shadforth MF, Goldberg SK, Davis JS 4th. The role of immune complexes in the pathogenesis of pleural effusions. Am Rev Respir Dis 1981;124:115-20.
2. Zeng CQ, Alpert LC, Alpert E. Characterization of a lung-cancer- associated auto-antigen. Int J Cancer 1992;52:523-9.
3. Wang DY, Yang PC, Yu WL, Kuo SH, Hsu NY. Serial antinuclear antibodies titre in pleural and pericardial fluid. Eur Respir J 2000;15:1106-10.
4. Yamamoto A, Shimizu E, Sumitomo K, et al. L-Myc overexpression and detection of auto-antibodies against L-Myc in both the serum and pleural effusion from a patient with non-small cell lung cancer. Intern Med 1997;36:724-7.
5. Miedouge M, Rouzaud P, Salama G, et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 1999;81:1059-65.
6. Amirghofran Z, Sheikhi AK, Kumar PV, Saberi Firouzi M. Soluble HLA class I molecules in malignant pleural and peritoneal effusions and its possible role on NK and LAK cytotoxicity. J Cancer Res Clin Oncol 2002;128:443-8.
7. Pancholi V. Multifunctional α-enolase: its role in diseases. Cell Mol Life Sci 2001;58:902-20.
8. Redlitz A, Fowler BJ, Plow EF, Miles LA. The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 1995;227:407-15.
9. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression Cancer Res 1997;57:5328-35.
10. Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A. ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett 2000;473:47-52.
11. Gitlits VM, Toh BH, Sentry JW. Disease association, origin, and clinical relevance of autoantibodies to the glycolytic enzyme enolase. J Investig Med 2001;49:138-45.
12. Gomm SA, Keevil BG, Thatcher N, Hasleton PS, Swindell RS. The value of tumour markers in lung cancer. Br J Cancer 1988;58:797-804.
13. Sato N, Nabeta Y, Kondo H, et al. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens. Cancer Chemother Pharmacol 2000;46:586-90.
14. Jankowska R, Witkowska D, Porebska I, Kuropatwa M, Kurowska E, Gorczyca WA. Serum antibodies to retinal antigens in lung cancer and sarcoidosis. Pathobiology 2004;71:323-8.
15. Li C, Xiao Z, Chen Z, et al. Proteome analysis of human lung squamous carcinoma. Proteomics 2006;6:547-58.
16. Peebles KA, Duncan MW, Ruch RJ, Malkinson AM. Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity has been abrogated by transfection with the gap junction structural gene for connexin 43, Gja1. Carcinogenesis 2003;24:651-7.
17. Zhang L, Cilley RE, Chinoy MR. Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines. J Surg Res 2000;93:108-19.
18. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 2002;19:319-26.
19. Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GE. Glycolytic enzyme activities in breast cancer metastases. Tumour Biol 1988;9:241-8.
20. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004;84:1014-20.
21. Chang YS, Wu W, Walsh G, Hong WK, Mao L. Enolase-α is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res 2003;9:3641-4.
22. Takashima M, Kuramitsu Y, Yokoyama Y, et al. Overexpression of α enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 2005;5:1686-92.
23. Chen YM, Tsai CM, Whang-Peng J, Perng RP. Double signal stimulation was required for full recovery of the autologous tumor-killing effect of effusion-associated lymphocytes. Chest 2002;122:1421-7.
24. Masuda N, Fukuoka M, Takada M, Kudoh S, Kusunoki Y. Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4). Chest 1991;100:429-38.
25. Ueyama H, Sasaki I, Shimomura K, Suganuma M. Specific protein interacting with a tumor promoter, debromoaplysiatoxin, in bovine serum is α1-acid glycoprotein. J Cancer Res Clin Oncol 1995;121:211-8.
26. Nesterenko MV, Tilley M, Upton SJ. A simple modification of Blum's silver stain method allows for 30 minute detection of proteins in polyacrylamide gels. J Biochem Biophys Methods 1994;28:239-42.
27. Shin NY, Li J, Karpitskii V, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999;286:312-5.
28. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-51.
29. Andronicos NM, Ranson M, Bognacki J, Baker MS. The human ENO1 gene product (recombinant human α-enolase) displays characteristics required for a plasminogen binding protein. Biochim Biophys Acta 1997;4:27-39.
30. Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003;22:3180-7.
31. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800
32. Muller AJ, Duhadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9.
33. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5:938-42.
34. Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003;111:363-70.
35. Pertovaara M, Raitala A, Uusitalo H, et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjogren's syndrome. Clin Exp Immunol 2005;142:155-61.
36. Yang XF, Wu CJ, Chen L, et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 2002;62:5517-22.
37. Ohanian SH, Schlager SI. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense. Crit Rev Immunol 1981;1:165-209.
38. Veiga-Malta I, Duarte M, Dinis M, Tavares D, Videira A, Ferreira P. Enolase from Streptococcus sobrinus is an immunosuppressive protein. Cell Microbiol 2004;6:79-88.
39. Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996;271:32529-37.
40. Kim JW, Zeller KI, Wang Y, et al. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 2004;24:5923-36.
41. Holland JP, Labieniec L, Swimmer C, Holland MJ. Homologous nucleotide sequences at the 5′ termini of messenger RNAs synthesized from the yeast enolase and glyceraldehyde-3-phosphate dehydrogenase gene families. The primary structure of a third yeast glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem 1983;258:5291-9.
42. Arza B, Felez J, Lopez-Alemany R, Miles LA, Munoz-Canoves P. Identification of an epitope of α-enolase (a candidate plasminogen receptor) by phage display. Thromb Haemost 1997;78:1097-103.
43. Gould VE, Lee I, Warren WH. Immunohistochemical evaluation of neuroendocrine cells and neoplasms of the lung. Pathol Res Pract 1988;183.200-13.
44. Haimoto H, Takahashi Y, Koshikawa T, Nagura H, Kato K. Immunohistochemical localization of γ-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 1985;52:257-63.